Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-02-12

Clinical Trial Update: Prevention of Delirium in Inpatients Utilizing Melatonin [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial assessing melatonin for prevention of delirium in inpatients was terminated; results were posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Melatonin (melatonin)

Snippet

Sponsor: Yale University | Conditions: Delirium | Phase 3 | Status: TERMINATED | Results posted: 2019-02-12